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BACKGROUND AND PURPOSE
A non-psychoactive phytocannabinoid, cannabidiol (CBD), shows promising results as an effective potential antiepileptic drug in
some forms of refractory epilepsy. To elucidate the mechanisms by which CBD exerts its anti-seizure effects, we investigated its
effects at synaptic connections and on the intrinsic membrane properties of hippocampal CA1 pyramidal cells and two major
inhibitory interneurons: fast spiking, parvalbumin (PV)-expressing and adapting, cholecystokinin (CCK)-expressing interneurons.
We also investigated whether in vivo treatment with CBD altered the fate of CCK and PV interneurons using
immunohistochemistry.
EXPERIMENTAL APPROACH
Electrophysiological intracellular whole-cell recordings combined with neuroanatomy were performed in acute brain slices of rat
temporal lobe epilepsy in in vivo (induced by kainic acid) and in vitro (induced by Mg2+-free solution) epileptic seizure models. For
immunohistochemistry experiments, CBDwas administered in vivo (100mg·kg1) at zero time and 90min post status epilepticus,
induced with kainic acid.
KEY RESULTS
Bath application of CBD (10 μM) dampened excitability at unitary synapses between pyramidal cells but enhanced inhibitory
synaptic potentials elicited by fast spiking and adapting interneurons at postsynaptic pyramidal cells. Furthermore, CBD restored
impaired membrane excitability of PV, CCK and pyramidal cells in a cell type-speciﬁc manner. These neuroprotective effects of
CBD were corroborated by immunohistochemistry experiments that revealed a signiﬁcant reduction in atrophy and death of PV-
and CCK-expressing interneurons after CBD treatment.
CONCLUSIONS AND IMPLICATIONS
Our data suggest that CBD restores excitability and morphological impairments in epileptic models to pre-epilepsy control levels
through multiple mechanisms to reinstate normal network function.
Abbreviations
ACSF, artiﬁcial CSF; AMPA, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid; CB1, cannabinoid type-1; CBD,
cannabidiol; CCK, cholecystokinin; DG, dentate gyrus; FS, fast spiking; HW, width at half amplitude; KA, kainic acid; PFA,
paraformaldehyde; PPR, paired pulse ratio; PV, parvalbumin; RT, rise time; SCA, Schaffer collateral-associated; SE, status
epilepticus; sEPSP, spontaneous EPSP; sIPSP, spontaneous IPSP; TBS-T, Triton X-100 in Tris-buffered saline; TLE, temporal
lobe epilepsy; TRPV, transient receptor potential vanilloid
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Introduction
Temporal lobe epilepsy (TLE) is the most common subtype of
epilepsy in human patients (Wiebe, 2000) that results in ste-
reotyped pathological changes including a common
aetiology of hippocampal sclerosis. TLE can be examined in
an array of animal TLEmodels, unlike other human epilepsies
(Kandratavicius et al., 2014; Levesque et al., 2016). Factors
such as cell death, neurogenesis and neuronal circuit reorga-
nization have been attributed as causes of the disease process
(Alexander et al., 2016), as well as a prominent long-standing
hypothesis of the primary cause of epilepsy – ion channel ab-
normalities. Although ion channel defects can explain the
onset of seizure events, they do not in all cases describe the
physiological alterations that occur during the latent period
of epileptogenesis – the process by which the brain develops
epilepsy. The balancing of cellular events is performed by ex-
citatory pyramidal cells and specialized inhibitory GABA
neurons that comprise approximately 10–15% of cortical
neurons (Ascoli et al., 2008), and it is generally accepted that
the spread of epileptiform discharges involves a primary
dysfunction of interneurons (Buhl et al., 1996; Prince et al.,
1997; DeFelipe, 1999; Bausch, 2005). The fate of interneurons
depends upon the subtype, and the diverse roles that
interneurons play in epilepsy are becoming more evident;
for example, seizure susceptibility is apparent in patients
with reduced inhibitory circuitry (Wittner et al., 2005; Liu
et al., 2014).
Several studies report the loss of hippocampal inhibitory
interneurons in rodent models of epilepsy (Cavazos et al.,
1994; Fritschy et al., 1999; Bouilleret et al., 2000; Gorter
et al., 2001), as well as in human epileptic patients (Andrioli
et al., 2007). These observations are further corroborated by
genetic studies using interneuron-deﬁcient transgenic mice
suggesting that particular gene defects affect speciﬁc inter-
neuronal development, resulting in seizures (Jones-Davies
et al., 2009). In general, these studies infer that the loss of in-
terneurons has a negative impact on the balance of overall
neuronal circuitry, which has been challenged by other re-
search groups who suggest that speciﬁc interneuronal loss re-
sults in the preservation of lateral inhibitory circuits
(Buckmaster and Jongen-Relo, 1999). Therefore, it appears
that the fate of interneurons in the epileptic brain, particu-
larly the hippocampus, still remains largely ambiguous and
unresolved.
Currently, there is a lack of effective treatments to prevent
the progression of epileptogenesis, which is further compli-
cated with the development of pharmacoresistance to con-
ventional antiepileptic agents. Effective treatment of all
types of epilepsy is therefore an unsolved problem in the
ﬁeld, resulting in a higher fraction of failed/inadequate sei-
zure control in epileptic patients; thus, there is a continuing
need for a better understanding of the cellular changes of ep-
ilepsy and epileptogenesis, as well as more effective and bet-
ter tolerated antiepileptic drugs with better deﬁned
mechanisms of action.
One particular area of recent interest to researchers and clini-
cians has been the potential use of non-psychoactive
phytocannabinoids such as cannabidiol (CBD) or its ana-
logue cannabidivarin, also known as GWP42006 (Hill et al.,
2012a; Bialer et al., 2015), in the treatment of epilepsy,
particularly the more refractory, drug-resistant forms (Ibeas Bih
et al., 2015; Devinsky et al., 2017; Gaston and Friedman, 2017).
Previous studies have shown that CBD can dampen hip-
pocampal epileptiform activity in both in vitro and in vivo an-
imal models, without the psychotropic side effects associated
with other phytocannabinoids (i.e. Δ9-tetrahydrocannab-
inol, Δ9-THC) that act through cannabinoid type-1 (CB1) re-
ceptors (Consroe and Wolkin, 1977; Consroe et al., 1982;
Kogan and Mechoulam, 2007; Jones et al., 2010; 2012), mak-
ing the cannabinoid system an interesting and novel thera-
peutic target for epilepsy. These observations have been
corroborated by recent human clinical studies, where CBD re-
duced the convulsive seizure frequency by 50%, giving hope
for patient groups with uncontrollable epilepsy where other
drug treatments have failed, namely, in a complex childhood
epilepsy disorder associated with high mortality rate, Dravet
syndrome (Devinsky et al., 2017). This syndrome is associated
with sodium channel mutations that may have speciﬁc ef-
fects on interneurons, reducing interneuronal excitability.
Like most antiepileptic drugs, CBD is thought to have
multiple targets, and further investigations are clearly re-
quired to elucidate the cellular mechanisms through which
CBD exerts its anti-seizure effects as well as any possible
neuroprotectant activity. Studying single channels does not
inform us about whether a drug would decrease the excitation
of interneurons or pyramidal cells; for example, we know that
antiepileptic drugs such as sodium channel blockers affect
both excitation and inhibition that can worsen epilepsy
when there is a deﬁcit in interneuronal excitability as in
Dravet’s syndrome (Rubinstein et al., 2015). Therefore, we
have taken an alternative, novel approach and addressed the
functional impact of CBD treatment on excitatory and inhib-
itory local circuits in epilepsy. Our general hypothesis is that
the intrinsic membrane properties of pyramidal cells and the
two major subclasses of interneurons: fast spiking (FS),
parvalbumin (PV)-expressing and adapting, cholecystokinin
(CCK)-expressing interneurons are altered, leading to im-
paired local circuit activity in the hippocampus during epi-
lepsy, and that the activity of these cells and their local
circuit functionwill be restored by CBD, due to a neuroprotec-
tive effect. Using electrophysiological techniques, we initially
investigated whether CBD could alter the epilepsy-induced
synaptic and biophysical properties of pyramidal cells, PV-
and CCK-expressing interneurons, in an established rodent
model of epilepsy. We then investigated whether CBD treat-
ment could alter the fate of these twomajor interneuron types
in the epileptic brain using anatomical studies.
Methods
Animals
Animal studies are reported in compliance with the ARRIVE
guidelines (Kilkenny et al., 2010; McGrath and Lilley, 2015).
All experiments were performed in accordance with British
Home Ofﬁce regulations under the Animal Scientiﬁc Proce-
dure Act 1986. Home Ofﬁce project licences held by the PI
(AA: PPL No. 7007558) and were approved by internal and ex-
ternal ethical review panels. Adult male Sprague–Dawley rats,
between postnatal days 42 and 56 and weighing between 200
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and 250 g, were used in this study. All animals were housed on
a 12 h light-dark cycle, with food and water available ad
libitum.
Epileptic models
Two seizuremodels were used, in vivo kainic acid (KA)-induced
epilepsy and an in vitro Mg2+-free hippocampal brain slice
model (see below). For the KA model, animals were rendered
epileptic by the administration of a single i.p. injection of
KA, at a dose of 10 mg·kg1 (Ben-Ari and Cossart, 2000). The
severity of seizures was scored using the Racine (1972) scale,
and seizures of grade 5 (i.e. rearing, bilateral forelimb clonus
and falling with loss of postural control) were accepted. The
onset of spontaneous seizures occurred between 30 and
100 min after the injection of KA. The animals were further
monitored until the full development of status epilepticus
(SE). To minimize mortality related to SE, sustained seizures
were terminated by a single injection of diazepam at a dose
of 10mg kg-1, i.p., as required by the HomeOfﬁce regulations.
The duration of SE was measured based on behavioural mani-
festations, and onset of SE was considered to occur when the
rat experienced full motor seizures with loss of postural con-
trol and falling. Rats were maintained for a further 2 weeks
post-KA injection to ensure the development of spontaneous
seizures, before using them either for electrophysiological
in vitro experiments or for neuroanatomical studies.
For neuroanatomical studies, rats were randomly assigned
to one of the four experimental groups: (i) healthy control
(n = 5 rats); (ii) epileptic_vehicle [single injection of vehicle
(10% DMSO/saline), at a time interval of 2 weeks post-SE
onset, n = 6 rats]; (iii) CBD_time 0 [single injection of
100mg·kg1 CBD (Tocris Bioscience, UK), zero time interval
of the SE onset, n = 6 rats]; and (iv) CBD_time 90 (single
injection of 100 mg·kg1 CBD, 90 min interval post-SE onset,
n = 6). Substances were injected i.p. The dose of CBD injected
into rats was approximately the ED50 for animal seizure
models in the National Institute of Neurological
Disorders and Stroke screening (Jones et al., 2010).
All rats were anaesthetized via gas inhalation of
halothane (Fluothane) followed by sodium phenobarbital
injection (60 mg·kg1, i.p.) for electrophysiological and neu-
roanatomical studies. The level of anaesthesia was monitored
using pedal, tail pinch reﬂexes, rate, depth and pattern of res-
piration through observation and colour of mucous mem-
brane and skin.
Electrophysiology for in vitro recordings
Rats were anaesthetized and perfused with a sucrose-
containing artiﬁcial CSF (ACSF) solution that consisted the
following (in mM): 248 sucrose, 3.3 KCl, 1.4 NaH2PO4, 2.5
CaCl2, 1.2MgCl2, 15 glucose and 25.5 NaHCO3, bubbled with
95% O2 and 5% CO2. Following decapitation and removal of
the brain, coronal slices of cortex, 300 μm thick, were cut in
ice-cold ACSF using an automated vibratome (Leica,
Germany). This standard ACSF contained (inmM) the follow-
ing: 121 NaCl, 2.5 KCl, 1.3 NaH2PO4, 2 CaCl2, 1 MgCl2, 20
glucose and 26 NaHCO3, equilibrated with 95% O2 and 5%
CO2. Brain slices were placed in a submerged chamber and
super-perfused with ACSF at a rate of 1–2 mL·min1 for 1 h
at room temperature (20–23°C) prior to recording. To gener-
ate the in vitro Mg2+-free epileptic model, brain slices were
incubated in oxygenated (95%O2–5%CO2) ACSF, containing
(in mM) 121 NaCl, 2.5 KCl, 1.25 NaH2PO4, 2 CaCl2, 26
NaHCO3 and 20 glucose, for approximately 2 h.
Paired whole-cell somatic recordings were obtained be-
tween CA1 pyramidal cells (for excitatory connections) and
between interneurons and postsynaptic pyramidal cells (for
inhibitory connections). Patch electrodes with resistances of
8–11 MΩ were made from ﬁlamented borosilicate glass
capillaries (Harvard Apparatus, UK) and ﬁlled with a solution
containing (inmM): 134 K gluconate, 10 HEPES, 10 phospho-
creatine, 2 Na2ATP, 0.2 Na2GTP and 0.2% w
. v-1 biocytin.
Neurons were selected for recording based on the shape of
their soma using video microscopy under near infrared
differential interference contrast illumination and further
characterised by their electrophysiological properties ob-
tained from a series of 500 ms depolarising and
hyperpolarising current pulses. Action potential parameters
were measured from responses of depolarising current steps
(+50–150 pA, 500 ms), which induced a single or trains of ac-
tion potentials. The input resistance and membrane time
constant were determined from voltage changes in response
to hyperpolarising current steps (100 pA, 500 ms).
Unitary EPSPs or IPSPs were elicited by a depolarising cur-
rent step into the presynaptic neuron (+0.05 nA, 5–10 ms) re-
peated at 0.33 Hz. Spontaneous PSPs were recorded from cells
routinely held at55mVmembrane potential by injection of
steady depolarising current. Recordings were carried out in
the current clamp mode of operation (SEC 05LX npi ampli-
ﬁers; npi electronics, Germany), low pass ﬁltered at 2 KHz
and digitised at 5 KHz using a CED 1401 interface (Cambridge
Electronic Design, UK). Input resistance was monitored
throughout experiments by means of a hyperpolarising cur-
rent step (0.001 nA, 10 ms). Signal (Cambridge Electronic
Design) was used to acquire recordings and generate current
steps. The peak EPSP/IPSP amplitudes, 10–90% rise time
(RT) and width at half amplitude (HW) measurements were
obtained from averages including 100–200 unitary synaptic
events. Apparent failures of transmission were assigned a
value of 0 mV and were not included in averages.
For in vitro pharmacology studies, drugs such as CBD (5, 8
and 10 μM) and a selective antagonist of CB1 receptors
AM4113 (1 μM; Tocris Bioscience) were bath-applied.
Immunohistochemistry
After anaesthesia, intracardial perfusion was performed, with
PBS, followed by 4% paraformaldehyde (PFA) solution in
0.1 M PBS, pH 7.4 (200 mL.100 g-1 of body weight). The ani-
mals were then decapitated, and the brains were rapidly re-
moved and ﬁxed in a solution containing of 4% w.v -1 PFA,
0.025% v. v-1 glutaraldehyde, 0.2% v. v -1 picric acid in
0.1 M PBS, overnight. Coronal brain sections of 100 μm thick
were cut using a vibratome (Vibroslice, Camden Instrument,
Loughborough, UK) and washed in 0.1% Triton X-100 in
TBS (TBS-T), followed by incubation in 1% hydrogen
peroxide aqueous solution for 30 min. After further rinses in
TBS-T, sections were incubated in PBS containing 10%
normal goat serum (Sigma-Aldrich, USA) for 1 h at room
temperature. This followed incubation in the primary anti-
body solution, containing 1:5000 diluted anti-PV antibody
raised in rabbit (SWANT, UK) or 1:10 000 diluted anti-CCK
antibody raised in mouse (gift from Gordon Ohing, Cure,
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UCLA) and 1% horse serum in TBS-T, for 24 h at 4°C. After
washes in TBS-T, the sections were then incubated in second-
ary biotinylated anti-rabbit or anti-mouse antibodies raised
in goat (Vector Laboratories, UK), diluted at 1:500 for 24 h
at 4°C. This followed washes in TBS-T and a further incuba-
tion in avidin-biotin-horseradish peroxidase complex (Vec-
tor Laboratories) solution, for 2 h at room temperature. The
sections were then washed further in TBS-T and processed
for 3-3-diaminobenzidine and subsequently dehydrated and
mounted (see Ali, 2007).
Reconstruction of immunolabelled neurons and
analysis
Anatomical maps of immunopositive somata of PV and CCK
neurons in the hippocampal formation weremanually drawn
from three consecutive 100 μm-thick sections using a draw-
ing tube attached to a Leica DMRmicroscope under ×10 mag-
niﬁcation; the images were scanned and digitized to
superimpose the 300 μm sections to perform cell density
analysis using software, Image J (version 1.49, RBS, Maryland,
USA). PV- and CCK-expressing interneurons were recon-
structed using a drawing tube connected to a Leica DMR mi-
croscope with ×40 objective to investigate anatomical
changes and for Sholl analysis. Only complete, fully impreg-
nated interneurons with no apparent truncation of the den-
dritic arbor were included in this study. Sholl analysis was
performed on the reconstructed images using a preformed
template in Image J with a radius step size of 10 μm. The area
under the Sholl curve can be used as a measure of dendritic
complexity, and changes in this value are indicative of mor-
phological alterations (Ristanovic et al., 2006).
Statistical analyses
The data and statistical analysis comply with the recommen-
dations on experimental design and analysis in pharmacol-
ogy (Curtis et al., 2015). All data values are given as the
mean ± SD, unless otherwise stated. Student’s two-tailed,
paired t-test was used to compare two groups of data. For com-
parisons between more than two groups of data, a one-way
ANOVA statistical test was used, followed by a post hoc
Tukey’s test. All statistical analyses were conducted using
the statistical package Origin Pro 2016 SR1. Statistical signiﬁ-
cance was accepted where P < 0.05. The ‘n’ values represent
the number of observations and the number of animals used,
unless otherwise stated.
Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked
to corresponding entries in http://www.guidetopharma-
cology.org, the common portal for data from the
IUPHAR/BPS Guide to PHARMACOLOGY (Harding et al.,
2018), and are permanently archived in the Concise Guide
to PHARMACOLOGY 2017/18 (Alexander et al., 2017a,b,c).
Results
This study initially focused on investigating the effects of
CBD on the synaptic and biophysical properties of neurons
followed by neuroanatomical investigation in the CA1 hip-
pocampal subﬁeld.
CBD alters unitary synaptic connections,
favouring reduced seizure activity
To investigate whether CBD alters unitary synaptic events,
we ﬁrst investigated unitary excitatory connections be-
tween two pyramidal cells and then the inhibition elicited
by presynaptic FS, PV and presynaptic adapting CCK cells
onto postsynaptic pyramidal cells in the CA1 region of
the hippocampus. There are various subclasses of adapting
CCK cells in CA1; we focused on the Schaffer collateral-
associated (SCA) interneurons which are abundant in CA1
(Ali, 2007). All interneuron subtypes were conﬁrmed
anatomically.
CBD reduces excitation at pyramidal cells. Initial experiments
were performed to assess the effects of CBD on spontaneous
EPSPs (sEPSPs; Figure 1A). The mean frequency and
amplitude of sEPSPs recorded at a membrane potential of
60 mV in healthy control and KA-induced epileptic tissue
was 0.52 ± 0.23 Hz (0.57 ± 0.83 mV in amplitude, n = 5
pyramidal cells, n = 3 animals) and 1.74 ± 0.54 Hz
(1.62 ± 0.96 mV in amplitude, n = 5 pyramidal cells, n = 3
animals) respectively. Only signiﬁcant reductions in the
sEPSP frequency and amplitude were observed with 10 μM
bath application of CBD, which restored the sEPSPs
properties to control healthy levels of 0.55 ± 0.42 Hz
(0.86 ± 0.71 mV, P < 0.05, n = 5; Figure 1A).
For unitary connections, the probability of ﬁnding two
CA1 pyramidal cells that were synaptically connected was
low. Only one in 12 pairs of pyramidal cells tested yielded
a synaptic connection. We found that CBD exerted its ac-
tion at unitary excitatory synapses by reducing the ampli-
tude of EPSPs (Figure 1B). EPSPs elicited in excitatory
pyramidal cells by other pyramidal cells were reduced
(n = 5). The EPSP amplitude and duration were both de-
creased at all postsynaptic membrane potentials. However,
the effect of CBD was more pronounced at a depolarized
membrane potential (55 mV), reducing the amplitude sig-
niﬁcantly from 2.75 ± 1.40 mV (control) to 0.62 ± 0.31 mV
after 10 μM CBD bath application (n = 5, P < 0.05). In com-
parison, at a more negative postsynaptic membrane poten-
tial of 70 mV, the mean change of the amplitudes was
reduced from 3.33 ± 2.10 to 2.48 ± 1.90 mV with bath appli-
cation of CBD (n = 5, P > 0.05). This suggests that the EPSPs
elicited at postsynaptic pyramidal cells are signiﬁcantly af-
fected by CBD at more depolarized levels of excitation. Syn-
aptic connections typically possessed a non-conventional
voltage relationship in the current study (Figure 1B–D),
where EPSP amplitudes decreased in peak amplitude from
a holding potential of 70 to 60 mV; however, beyond a
membrane holding a potential of 58 mV, the EPSP in-
creased in amplitude and duration. These connections also
typically displayed synaptic depression, as indicated by the
average paired pulse ratio (PPR) (second-amplitude
EPSP/ﬁrst-EPSP amplitude) at 55 mV, 0.25 ± 0.13 (n = 5),
which was not signiﬁcantly changed with bath application
of CBD, 0.32 ± 0.17 (Figure 1E), suggesting a postsynaptic
mechanism of action. CBD did not signiﬁcantly change
the EPSP RT or the duration at either membrane
potentials, which were in the range of 2.5 and 3.5 ms and
14 and 21 ms respectively.
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Enhanced inhibition. In contrast to excitation, spontaneous
IPSPs (sIPSP) recorded in pyramidal cells and unitary IPSPs
elicited by FS and adapting CCK (SCA cells) cells onto
postsynaptic pyramidal cells held at 55 mV were both
enhanced by bath application of CBD (Figure 2A). The mean
sIPSPs amplitude and frequency were enhanced by 45 ± 7.8
and 38.5 ± 10%, of the control values with bath application
of 10 μM CBD respectively (n = 4 postsynaptic pyramidal
cells, n = 3 animals). These events were unchanged with
subsequent bath application of a selective antagonist of CB1
receptors, AM41131 (1 μM), shown in Figure 2A.
Unitary IPSPs elicited by FS cells displayed a fast RT
(Figure 2B, panels i–iii; 10–90% RTs range, 7–10 ms; HW
range; 30–51 ms), with an average peak amplitude of
1.06 ± 0.56 mV (n = 4). This amplitude increased to
1.93 ± 1.04 mV and thus by 182% of control amplitude with
bath application of CBD (n = 4).
The IPSPs elicited by adapting SCA cells displayed slower
RTs (10–90% RTs range, 8–11 ms; HW range; 40–65 ms; see
Figure 2C, panels i–iii). The average peak amplitude was
1.37 ± 0.76 mV (n = 6), which was also enhanced to
2.09 ± 0.98 mV of control amplitude by CBD, a signiﬁcant in-
crease by 150 ± 25% of control (n = 6, P < 0.05).
CBD exerts a cell type-specific alteration of
membrane properties of CA1 neurons
The intrinsic membrane properties of neurons reveal infor-
mation about how a cell will relay information in the
network. It is well documented that principal pyramidal
cells show hyperactivity in epileptic tissue; hence, we
investigated the intrinsic membrane properties of FS (PV),
adapting (CCK) and pyramidal cells in healthy rats and in
two different seizure models: the in vivo KA model of
epilepsy and the in vitro Mg2+-free brain slice model
(see Table 1 for quantitative data and statistical signiﬁ-
cance). In the KA model of epilepsy, all three cell types
were signiﬁcantly affected in their membrane properties,
indicative of the severity of this model in recapitulating
human TLE.
Principal pyramidal cells display adapting action poten-
tial properties with slow kinetics compared to the other
hippocampal neuronal subpopulations studied in healthy
control rats (Table 1, Figure 3). After 20 min of bath appli-
cation of 10 μM CBD, signiﬁcant changes in the intrinsic
membrane properties included a reduced number of spikes
and a decreased input resistance in healthy control rats
(Figure 3). In general, hippocampal pyramidal cells were
Figure 1
CBD dampens excitation. (A) Spontaneous EPSPs, recorded at a membrane potential of60 mV in healthy control tissue and KA model of epilep-
tic tissue. Concentrations of 5, 8 and 10 μM CBD were bath-applied. sEPSP frequency and peak amplitudes were only signiﬁcantly changed with
10 μM of CBD. (B) Unitary recording between two pyramidal cells synaptically connected. Triple presynaptic action potentials elicited by the py-
ramidal cell resulted in EPSPs that displayed synaptic depression recorded at three different membrane potentials (70,60 and55 mV). These
EPSPs were reduced in amplitude and duration following bath application of 10 μΜ CBD (red traces). (C, D) Plots of change in peak average am-
plitude of EPSPs per synaptic connection (n = 5) with bath application of CBD recorded at 55 and 70 mV. CBD had a more pronounced action
at more positive membrane potentials. (E) Plot of PPR (second-amplitude EPSP/ﬁrst-amplitude EPSP) at55 and70 mV; no signiﬁcant change in
PPR was measured in CBD-treated cells.
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Figure 2
CBD enhances inhibition. (A, panels i, ii) sIPSPs, recorded at a membrane potential of 55 mV. The frequency and peak amplitudes of sIPSPs in-
creased with CBD (10 μM) and remained unchanged with subsequent addition of a selective CB1 receptor antagonist AM4113 (1 μM). (B, panels i,
ii) Unitary connection between a presynaptic FS PV containing interneuron (FS-PV) and a postsynaptic excitatory cell is shown. Averaged IPSPs are
shown as black traces (in control) and after bath application 10 μM CBD (20–30 min, red traces). (B, panels i, ii.) IPSPs elicited by CCK, SCA inter-
neuron onto postsynaptic pyramidal cells. The top traces in (A) and (B) left panel show the averaged IPSPs elicited by one presynaptic action po-
tential, whereas the bottom panel shows the inhibition elicited by a train of presynaptic interneuron action potentials; as a result, there is
summation of the inhibitory event. (C, panels i,– ii) Plots show the average change in IPSP amplitudes, IPSP RTs and width at half amplitude elicited
by FS-PV and CCK, SCA presynaptic interneurons onto pyramidal cells with bath application of CBD. The line plots show change in peak average
IPSP amplitude with CBD per individual synaptic connection.
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hyper-excited in both the in vivo KA model and the in vitro
Mg2+-free model, as evidenced by a higher number of ac-
tion potential discharge and enhanced input resistance re-
corded at a ﬁxed membrane potential of 60 mV
(Figure 3D). In these models, bath application of CBD also
resulted in signiﬁcant changes by reducing the number of
spikes, the input resistance and time constant of the cells.
A rightward shift of the control output curves representing
number of evoked spikes plotted against increasing
depolarizing current injections (Figure 3A, panel iii, B,
panel iii, C, panel iii) indicated the suppression of excit-
ability induced by CBD in pyramidal cells. CBD caused a
negligible increase in mean action potential threshold in
pyramidal cells; also, the mean action potential half-width,
amplitude and spike after-hyperpolarization (AHP) ampli-
tude showed no statistically signiﬁcant differences in the
experimental groups. Interestingly, bath application of
CBD also resulted in 10 mV hyperpolarization of the mem-
brane potential.
Effect of CBD on the intrinsic membrane
properties of adapting cells that express
neuropeptide CCK
In general, CCK SCA cells displayed intermediate action
potential duration (0.3–0.5 ms in spike width; Figure 4).
Table 1
Electrophysiological properties of healthy control, Mg2+-free and KA-induced epileptic hippocampal cells under CBD treatment
Healthy control rats
Pyramidal cells (n = 13) Adapting cells (n = 11) FS cells (n = 9)
Subclass of cells Control CBD Control CBD Control CBD
AP Amp (mV) 76.02 ± 2.24 73.60 ± 1.77 81.45 ± 2.51 84.62 ± 6.23 71.66 ± 1.23 70.45 ± 2.02
AP HW (ms) 1.83 ± 0.07 3.35 ± 1.56 1.43 ± 0.14 1.52 ± 0.15 1.28 ± 0.16 1.28 ± 0.16
AP threshold (mV) 26.11 ± 1.76 27.59 ± 2.98 20.96 ± 2.04 23.84 ± 2.72 26.15 ± 3.43 18.72 ± 1.37*
AP AHP Amp (mV) 4.94 ± 0.80 5.47 ± 0.87 6.40 ± 0.59 6.50 ± 0.74 11.50 ± 0.82 12.02 ± 0.47
Input resistance (MΩ) 290.08 ± 15.75 241.21 ± 14.10* 305.42 ± 35.11 245.21 ± 29.62* 289.60 ± 38.00 396.84 ± 52.64*
TC (ms) 13.58 ± 1.90 10.42 ± 0.36* 12.82 ± 1.24 11.47 ± 0.82* 10.06 ± 0.44 14.23 ± 0.49*
No. of spikes at +150 pA 8.90 ± 0.61 5.40 ± 0.35* 12.09 ± 1.06 6.45 ± 0.76* 15.50 ± 2.88 22.25 ± 2.96**
Mg2+-free epileptic model
Pyramidal cells (n = 5) Adapting cells (n = 5) FS cells (n = 4)
Subclass of cells Control CBD Control CBD Control CBD
AP Amp (mV) 78.36 ± 3.41 76.93 ± 3.83 88.26 ± 6.42 71.75 ± 18.71 75.54 ± 9.83 72.33 ± 8.27
AP HW (ms) 2.01 ± 0.18 2.20 ± 0.38 1.22 ± 0.16 1.32 ± 0.14 1.58 ± 0.43 1.52 ± 0.41
AP threshold (mV) 24.80 ± 1.83 25.80 ± 2.99 25.85 ± 1.54 21.27 ± 5.58 28.70 ± 5.80 21.24 ± 2.55
AP AHP Amp (mV) 6.05 ± 0.74 5.37 ± 0.48 6.54 ± 0.83 6.05 ± 1.74 2.64 ± 1.29 4.49 ± 1.95
Input resistance (MΩ) 308 ± 16.55 227.60 ± 21.35* 289.06 ± 36.67 244.92 ± 37.83* 351.45 ± 46.36 396.20 ± 65.74
TC (ms) 14.06 ± 1.23 10.03 ± 0.68* 8.28 ± 1.73 8.74 ± 0.72 8.75 ± 0.60 12.08 ± 0.63
No. of spikes at +150 pA 12.80 ± 1.20 4.25 ± 0.22* 10.20 ± 0.66 4.60 ± 0.51* 10.75 ± 1.49 17.75 ± 2.87
KA-induced epileptic model
Pyramidal cells (n = 12) Adapting cells (n = 12) FS cells (n = 7)
Subclass of cells Control CBD Control CBD Control CBD
AP Amp (mV) 79.42 ± 2.81 78.33 ± 2.55 81.78 ± 3.34 77.67 ± 1.66 74.61 ± 2.39 75.46 ± 2.41
AP HW (ms) 2.14 ± 0.10 2.43 ± 0.18 1.59 ± 0.13 1.84 ± 0.11 1.34 ± 0.21 1.32 ± 0.18
AP threshold (mV) 27.61 ± 2.65 27.31 ± 3.57 26.76 ± 2.87 27.41 ± 2.75 19.12 ± 1.67 15.74 ± 1.85*
AP AHP Amp (mV) 2.42 ± 0.25 2.46 ± 0.33 7.23 ± 1.70 4.62 ± 0.64 12.00 ± 1.09 10.59 ± 1.57
Input resistance (MΩ) 313.84 ± 25.44 272.04 ± 25.42* 364.49 ± 43.35 285.65 ± 43.12* 372.63 ± 43.55 411.34 ± 51.50
TC (ms) 14.98 ± 0.74 10.58 ± 1.16* 10.25 ± 0.56 7.99 ± 0.42* 9.50 ± 0.81 12.21 ± 0.77*
No. of spikes at +150 pA 14.18 ± 0.28 4.92 ± 0.48* 12.36 ± 1.60 7.64 ± 1.23* 10.00 ± 0.71 21.43 ± 3.21*
AP, action potential; Amp, amplitude; HW, half-width; AHP, after-hyperpolarization; TC, time constant; FS, fast spiking.
Results are expressed as mean ± SEM.
*P < 0.05.
Student’s two-tailed paired t-test was used to compare between control and CBD treatment conditions of different biophysical properties of each cell-
type.
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In healthy control rats, CBD (10 μΜ) altered the membrane
properties of adapting, CCK-expressing cells, by signiﬁ-
cantly decreasing the mean number of spikes generated in
response to depolarizing current injections of 500 ms
(Figure 4A, panel i, to C, panel ii; see also Ali, 2007). A de-
creased mean input resistance and time constant was ob-
served in healthy control SCA cells with CBD treatment
(Figure 4D). These changes were also consistent in the
Mg2+-free and KA seizure models (see Table 1). A rightward
shift illustrated in the control scatter plot (representing
number of spikes at increasing positive current injections)
was observed indicating the reduction of the CCK SCA cell
excitability with CBD treatment in healthy controls and
both epileptic/seizure models (Figure 4A, panel iii, B, panel
iii, C, panel iii). No signiﬁcant differences of mean action
potential amplitude, half-width, threshold or AHP were ob-
served after bath application of CBD in any of the experi-
mental groups. Bath application of CBD also resulted in a
10 mV hyperpolarization of the membrane potential as
seen in pyramidal cells.
FS interneurons, typically expressing PV, showed char-
acteristic fast action potential kinetics and high frequency
of action potential discharge (with little spike frequency
adaption and accommodation), consistent with a fast
Figure 3
Pyramidal cell’s hyperactive membrane properties are restored by CBD. The intrinsic membrane properties of pyramidal cells recorded in healthy
rats in (A, panel i) control and (A, panel ii) after 10 μΜ CBD bath application. Similarly, pyramidal cells recorded brain slices in (B, panel i), (B, panel
ii) Mg2+-free and from (C, panel i), (C, panel ii) KA epileptic models. The input–output curves displayed a pseudo-linear relationship between the
number of spikes generated by pyramidal cells of (A, panel iii) healthy rodents (n = 13), (B.iii) Mg2+-free (n = 5) and (C, panel iii) KA (n = 12) ep-
ileptic models with increasing current injections. The ﬁring of pyramidal cells was decreased after application of CBD. (D) Bar plots representing
intrinsic membrane properties of pyramidal cells in Mg2+-free (n = 5) and KA epileptic models (n = 12) in comparison to healthy rodents (n = 13).
(D, panel i) CBD produced no apparent changes of action potential (AP) threshold of pyramidal cells. (D, panel ii) The input resistance and
(D, panel iii) time constant were decreased by CBD. Results are expressed as mean ± SEM. *P ≤ 0.05.
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membrane time constant (Table 1, Figure 5). The general
health of FS interneurons recorded was substantially im-
paired when recorded particularly in the KA model, which
showed a reduced action potential threshold, increased
spike frequency adaption and accommodation, with re-
spect to control FS cells, with the same amount of step de-
polarization (Figure 5A, panel i, to C, panel ii). However,
these cells were unable to sustain a high frequency of ﬁring
(Figure 5B, panel i), suggesting impaired membrane proper-
ties. Following a 20 min bath application of CBD (10 μM),
the number of action potentials increased with the same
amount of depolarizing current injections as control condi-
tions observed in brain slices of healthy control rats and in
the Mg2+-free and KA epilepsy models (Figure 5). This ob-
servation was consistent with signiﬁcant increases in input
resistance for the same hyperpolarizing current steps
Figure 4
CBD reduces intrinsic excitability of CCK adapting interneurons in CA1. The membrane properties of SCA interneurons, which were CCK positive,
were recorded in healthy rats (A, panel i) in control and (A, panel ii) after 10 μΜ CBD bath application. Similar recordings are shown in Mg2+-free
condition (B, panel i), (B, panel ii) and in the KA epileptic model (C, panel i), (C, panel ii). The input–output curves displayed a pseudo-linear re-
lationship between the number of spikes generated by adapting cells of (A, panel iii) healthy rodents (n = 11), (B, panel iii) Mg2+-free (n = 5) and
(C, panel iii) KA (n = 12) epileptic models with increasing current injections. The number of action potentials of adapting interneurons was de-
creased after application of CBD. (D) Bar plots representing intrinsic membrane properties of adapting cells in Mg2+-free (n = 5) and KA epileptic
models (n = 12) in comparison to healthy rodents (n = 11). (D, panel i) CBD produced no apparent changes of action potential (AP) threshold of
adapting cells. (D, panel ii) The input resistance and (D, panel iii) time constant were decreased by CBD in the disease models. Results are
expressed as mean ± SEM. *P ≤ 0.05.
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injected as in control conditions and an increased time
constant (Figure 5D). Higher input resistance shows a
greater change in membrane voltage in the presence of
CBD, suggesting a favourable enhanced excitability of FS
PV cells with this drug. Enhanced ﬁring of FS cells with
bath application of CBD and input resistance was also cor-
related with a signiﬁcant reduction of mean action poten-
tial threshold and faster mean time constants (Figure 5D),
which was consistent in all three experimental conditions
studied (see Table 1). Similar to pyramidal cells and
adapting SCA cells, bath application of CBD also resulted
in a 10 mV hyperpolarization of the membrane potential
in FS cells.
Changes in PV- and CCK-expressing
interneuron density and morphology in epilepsy
and after CBD treatment
The mean cell density of the PV- and CCK-expressing neu-
rons in three subﬁelds of the rat hippocampal formation in-
cluding CA1, CA3 and the dentate gyrus (DG) was ﬁrst
studied and compared between control animals and the KA
Figure 5
CBD enhances excitability of FS-PV interneurons in the CA1 region of the hippocampus. Themembrane properties of FS-PV interneurons recorded
in healthy rats (A, panel i) in control and (A, panel ii) after a 10 μΜ CBD bath application. Similarly, FS-Pv cells were also recorded in Mg2+-free
(B, panel i), (B, panel ii) and in KA epileptic models (C, panel i), (C, panel ii). The input–output curves displayed a pseudo-linear relationship be-
tween the number of spikes generated by FS PV cells of (A, panel iii) healthy rodents (n = 9), (B, panel iii) Mg2+-free (n = 4) and (C, panel iii) KA
(n = 7) epileptic models with increasing current injections. The ﬁring of FS-PV interneurons was dramatically increased after application of CBD.
(D) Bar plots representing intrinsic membrane properties of FS PV cells in Mg2+-free (n = 4) and KA epileptic models (n = 7) in comparison to
healthy rodents (n = 9). (D, panel i) CBD produced a reduction of action potential (AP) threshold of FS PV cells. (D, panel ii) The input resistance
and (D, panel iii) time constant were increased by CBD in healthy rodents and the seizure models. Results are expressed as mean ± SEM. *P ≤ 0.05.
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epileptic model. In all three subﬁelds, there was a signiﬁcant
reduction in the density of PV- and CCK-expressing neurons
in epileptic rats in comparison to control rats (see Table 2).
CA1 was examined in more detail, and there was a decrease
in the number of PV- and CCK-expressing cells in stratum
oriens (SO), stratum pyramidale (SP), stratum radiatum
and stratum lacunosum moleculare of epileptic rats. This
reduction in the cell densities was reduced by CBD at both
treatment time points (CBD_time0 and CBD_time90).
Figures 6 and 7 illustrate the dendritic morphology of PV-
and CCK-expressing interneurons in control rats and KA-
induced epileptic rats before and after treatment with
CBD. Morphometric analyses of these reconstructed neu-
rons were performed to compare the changes between con-
trol and epileptic rats after CBD treatment at time points, 0
and 90 min of SE. Sholl analysis, a measure of the distribu-
tion of dendritic complexity as a function of distance from
soma (Sholl, 1953), revealed a marked compromise of soma
size and dendritic arborization for both PV- and CCK-
expressing cells between control and the epileptic group
(Table 2), which was also prevented by CBD treatment, ir-
respective of the treatment time points.
In PV-expressing cell densities, signiﬁcant recovery of PV
was apparent in SO and SP in the epileptic rats, and 87 and
92% of control PV-expressing cells in SO were recovered at
CBD_time0 and CBD_time90 respectively. Similarly, a recov-
ery of 80 and 86% of control PV-expressing cells was seen in
SP at CBD_time0 and CBD_time90, respectively, suggesting
a better recovery after 90 min of SE.
PV-expressing cells present in epileptic rats exhibited a
Sholl proﬁle of a downward shift of the curve from the con-
trol curve (Figure 6A). In contrast, the Sholl proﬁle of PV-
expressing neurons of CBD-treated groups shifted upwards,
with a slight skewness of the curve to the left, from the con-
trol and epileptic groups (Table 2; Figure 6B). Furthermore,
analyses of mean length and number of primary and second-
ary dendrites of PV cells revealed a signiﬁcant reduction in
the epileptic animals in comparison to control. This dendritic
truncation seemed halted and elongated beyond control
levels when epileptic rats were treated with CBD (Figure 6C,
panels i, ii).
CCK-expressing cell densities also signiﬁcantly recovered
in all the three subﬁelds of the hippocampus after CBD treat-
ment, which was on par with healthy control levels with no
signiﬁcant differences between the control and CBD-treated
groups (Table 2, Figure 7).
The expression of CCK-expressing cells in epileptic rats
displayed a similar trend in the change of dendritic mor-
phology during epilepsy and after treatment with CBD
(Figure 7). The Sholl proﬁle of the CCK-expressing cells
of epileptic rats revealed a downward shift, suggesting a
deterioration in the dendritic arborisation in comparison
to the control rats. This shift was reversed by CBD treat-
ment, at both time 0 and time 90, resulting in the Sholl
proﬁle curves shifting upwards, with a slight skewness to-
wards the left, beyond the control levels. The dendrites
of CBD-treated CCK cells in comparison, regardless of the
time of treatment administration, appeared to ramify
mainly further from the soma with maximum branching
at a distance of approximately 114% increase in length
(Figure 7C).
Discussion
In this report, we investigated the cellular mechanisms of
action of CBD, which affected synaptic transmission, and
intrinsic excitability of pyramidal cells as well as PV-
expressing interneurons and CCK-expressing interneurons.
The pattern of progression of epilepsy in the KA model was
reminiscent of the development of TLE in humans, particu-
larly after a precipitating insult, such as focal brain trauma
or febrile seizures, which are some of the most common
causes of secondary TLE (Cavalheiro et al., 1982; Ben-Ari,
1985; Ben-Ari and Cossart, 2000). Therefore, this model is of
particular relevance to the human condition and offers a very
suitable platform to study the mechanisms of the disease and
also to evaluate potential novel treatments such as
cannabinoids.
Furthermore, our data suggest a neuroprotective role for
CBD, since treatment with CBD rescued the morphological
pathology of PV- and CCK-expressing interneurons induced
by epilepsy.
CBD reduces hyper-excitation via modulating
excitation and inhibition
CBD consistently reduced synaptic transmission at excitatory
synapses between pyramidal neurons. Interestingly, the re-
duction in EPSPs was dependent on the membrane potential
and the amount of presynaptic excitation. For example, ex-
citatory cells ﬁring at low frequencies at a less excitable state
(70 mV) were not signiﬁcantly affected by CBD but had
the most signiﬁcant affect at high ﬁring rates held at a more
excitable membrane potential (55 mV), which may be sec-
ondary to the voltage-dependent properties of CBD receptor
targets or to a voltage-dependent block of those targets by
CBD. As GPCR 55 (GPR55)-mediated Ca2+ elevation in hip-
pocampal glutamatergic terminals has been shown to in-
crease the probability of transmitter release, the
antagonizing action of CBD could also contribute to the re-
duced glutamate release and, as a consequence, reduce the ab-
errant glutamate-mediated excitation in the hippocampus
(Sylantyev et al., 2013). However, as indicated by the un-
changed PPR of EPSPs after CBD treatment in the present
study, we suggest a postsynaptic mechanism of action for this
cannabinoid.
GPR55 activation also leads to inhibition of Kv7.5
(M-type K+) channels, thereby increasing neuronal excit-
ability (Lauckner et al., 2008). Perhaps by activating Kv7.2
(M-channels), CBD reduces spontaneous and unitary EPSPs
in a voltage-dependent manner, which would help dampen
seizure-related hyperexcitability in the hippocampus and
thus limit the damage associated with excitotoxicity. This
could also contribute to the membrane hyperpolarisation
seen in pyramidal cells and the two classes of interneurons
studied in the presence of CBD. One other possibility is that
CBD has a similar effect to THC in activating postsynaptic
G-protein coupled inwardly rectifying potassium channels,
Kir channels. CBD has been reported to activate transient
receptor potential vanilloid (TRPV) channel subtypes,
which are ligand-gated, non-selective cation (Na+, Mg2+ and
Ca2+) channels (Billeter et al., 2014), at various potencies.
Agonism of human TRPV1 expressed in HEK293 cells by
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Figure 6
CBD halts PV cell death in the hippocampi of KA-induced epileptic rats. (A) Reconstructions and photomicrographs of all the PV neurons present in
the CA1 hippocampal subﬁeld of a randomly picked rat in (A, panel i) control, (A, panel ii) epileptic, (A, panel iii) CBD-treated at zero time
(CBD_time0) and (A, panel iv) at 90min (CBD_time90) post-SE conditions using a 40×magniﬁcation in a light microscope with an attached draw-
ing tube, from three consecutive 100-μm-thick coronal sections of rat hippocampi. The CA1 hippocampal subﬁeld including, SO, SP, and stratum
radiatum (SR) and stratum lacunosum moleculare (SLM). All photomicrographs taken of PV neurons were from brains sections processed using
immunoperoxidase labelling. Scale bars set at 250 μm for all the reconstructions and 50 μm for all the photomicrographs. (B, panel i) Sholl plot
exhibiting the pattern of dendritic arborisation of PV neurons in the CA1 hippocampal subﬁeld of rats in all experimental conditions, control, ep-
ileptic and CBD-treated at zero time (CBD_time0) and at time 90min (CBD_time90) post-SE (n = 20, for all). Morphometric analyses of PV neurons
(n = 20) were performed, which are represented as bar graphs comparing the (C, panel i) length of primary dendrites (μm), (C, panel ii) secondary
dendrites (μm) and (C, panel iii) area of soma (μm2) between all the experimental groups. Results are expressed as mean ± SEM (*P ≤ 0.05; one-
way ANOVA with post hoc Tukey’s test).
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Figure 7
CBD prevents CCK cell death in the hippocampi of KA-induced epileptic rats. (A) Reconstructions and photomicrographs of all the CCK neurons
present in the CA1 hippocampal subﬁeld of a randomly picked rat in (A, panel i) control, (A, panel ii) epileptic, (A, panel iii) CBD-treated at zero
time (CBD_time0) and (A.iv) at 90 min (CBD_time90) post-SE conditions using a 40× magniﬁcation in a light microscope with an attached draw-
ing tube, from three consecutive 100-μm-thick coronal sections of rat hippocampi. All photomicrographs taken of CCK neurons were from brains
sections processed using immunoperoxidase labelling. Scale bars set at 250 μm for all the reconstructions and 50 μm for all the photomicro-
graphs. (B, panel i) Sholl plot exhibiting the pattern of dendritic arborization of CCK neurons in the CA1 hippocampal subﬁeld of rats in all exper-
imental conditions, control, epileptic and CBD-treated at zero time (CBD_time0) and at time 90 min (CBD_time90) post-SE (n = 20, for all).
Morphometric analysis of CCK neurons (n = 20) were performed which are represented as bar graphs comparing the (C, panel i) length of primary
dendrites (μm), (C, panel ii) secondary dendrites (μm) and (C, panel iii) area of soma (μm2) between all the experimental groups. Results are
expressed as mean ± SEM (*P ≤ 0.05; one-way ANOVA with post hoc Tukey’s test).
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CBD has been popularly reported with different potencies
(3–10 μm) (Bisogno et al., 2001; De Petrocellis et al., 2011).
The existing literature surrounding the role of TRPV1 in epi-
lepsy is conﬂicted between different studies which indicate
that activation of TRPV1 has no involvement (von Ruden
et al., 2015), a proconvulsant (Manna and Umathe, 2012) or
an anticonvulsant (Chen et al., 2013; Gonzalez-Reyes et al.,
2013) effect in epilepsy. Whether CBD is directly modulating
AMPA or kainate receptors or targeting a novel postsyn-
aptic cannabinoid receptor or alternatively working in syn-
chrony with other previously established targets, for
example, GRP55 or TRPV receptors (De Petrocellis et al.,
2011; 2012; Hill et al., 2012b; Iannotti et al., 2014), remains
to be investigated.
CBD enhances inhibition on postsynaptic
pyramidal cells
The present study reports for the ﬁrst time that CBD en-
hances inhibition elicited by fast spiking PV and CCK inter-
neurons that display spike frequency accommodation and
adaptation, referred to as ‘adapting CCK cells’ connected to
postsynaptic pyramidal cells. This will ultimately lead to a
reduction in pyramidal cell activation and reduce hyper-
excitability. At present, we do not know the mechanism of
action of this effect at inhibitory synapses. However, previous
evidence suggests that CBD does not exert its pharmacologi-
cal effects via the GPCRs of the endocannabinoid system,
CB1 and CB2, to the same extent as THC, as it may possess a
low afﬁnity with little to almost no agonist activity on these
receptors (Pertwee, 2008). However, we found no change in
the CBD-mediated enhancement of inhibition with the selec-
tive CB1 receptor antagonist AM4113; therefore, the involve-
ment of CB1 receptors in our in vitro experiments can be
eliminated.
CBD changes the innate firing properties of
specific neurons in the hippocampus
Interneurons have a characteristic innate ﬁring pattern,
which tells us how fast information between neurons is re-
layed that may be a contributing factor in epileptogenesis
and ictogenesis. This study provides evidence, for the ﬁrst
time, to suggest that CBD alters the ﬁring of neurons in a cell
type-speciﬁc fashion. In both the KA and Mg2+-free seizure
models of epilepsy, FS cells exhibited a more excitable state
in their membrane properties with CBD, evidenced by a
lower threshold of ﬁring action potentials, an increase in
membrane time constant and input resistance, which will ul-
timately raise the neuron’s voltage level quicker and in turn
result in the cell beingmore readily available to ﬁre action po-
tentials. The precise mechanism of the increased excitability
of FS cells by CBD is unknown; it could be hypothesized that
CBD interacts with the membrane leak channels altering the
membrane permeability to sodium ions, or perhaps CBD di-
rectly modulates the calcium buffering capacity of PV within
FS cells changing the rate of ﬁring. The FS cells typically in-
nervate the soma and dendrites of pyramidal cells (Kawagu-
chi et al., 1987; Freund and Buzsaki, 1996) and therefore are
able to directly inhibit excessive excitatory discharge of pyra-
midal cells, enabling them to efﬁciently entrain and synchro-
nize neuronal networks. The effect of CBD resulting in an
enhanced neuronal discharge of FS cells will be a favoured
outcome in epilespy as a direct increase of inhibitory effects
which may contribute towards the supression of the disease
progression. In contrast, CBD favoured a reduced ﬁring of
adapting, CCK interneurons that play a role in network modu-
lation, as well as pyramidal cell ﬁring, evidenced by a decrease
in membrane time constant and input resistance in both the
KA and Mg2+-free models. Incidentally, a signiﬁcant loss of
principal pyramidal neurons in both human and rodent epi-
leptic hippocampi has been reported (Nadler et al., 1978; Babb
et al., 1989), despite others reporting additional axonal
sprouting of pyramidal cells, which will lead to enhancement
of excitatory networks between pyramidal neurons, and prob-
ably explains the hyperactivity (Perez et al., 1996; Esclapez
et al., 1999). Whether the CBD effects in reducing pyramidal
cell hyperactivity reported here lead to a perseveration of pyra-
midal cell structure needs further investigation.
Evidence suggests that a small conductance
Ca2+-activated K+ channel underlies the generation of the
slow spike AHP, which is important for spike frequency
accommodation and thus the ﬁring output of the neurons
(Lancaster and Nicoll, 1987; Sah and Isaacson, 1995; Sah
and Faber, 2002); although the exact channel associated with
this effect still remains unknown, some studies suggest that
an inhibition of Kv7.1 (KCNQ1) and Kv7.2 (KCNQ2)
channels blocks the slow AHP of hippocampal pyramidal
neurons (Shah et al., 2006). Whether CBD activates these
channels directly, enhancing the slow AHP effect to dampen
cell excitability, is yet to be fully investigated.
CBD halts morphological pathology of two
major interneuron subclasses in epilepsy
Our overall ﬁndings show a signiﬁcant reduction in the den-
sity in both PV- and CCK-expressing cells in the hippocam-
pus proper, including the CA1, CA3 and the DG.
Furthermore, we observed morphological changes in these
interneurons, which included distorted, shrunken somata
and altered, shorter dendritic arborisation and ramiﬁcation,
and an overall reduction in dendritic complexity. These dis-
tortions in the morphology and overall reduction in the cell
densities were halted by treatment of rats with CBD.
The reduction in cell densities are consistent with previ-
ous studies in epileptic rodents (Best et al., 1993; Buckmaster
and Dudek, 1997; Dudek et al., 2002;Wyeth et al., 2010; Jiang
et al., 2016); however, others have shown a loss of hippocam-
pal PV-expressing cells in tissue obtained from sclerotic pa-
tients despite the increase of total neuronal density in the
subiculum (Andrioli et al., 2007). Whether the loss of PV-
and CCK-immunoreactivity is due to cell death or the lack
of expression of the neuromarkers is still under debate. For
example, despite the loss of PV-expressing cell bodies and
dendrites, a preservation of the axon terminals together with
inhibitory input of pyramidal cells was reported in human
TLE using electron microscopy (Wittner et al., 2001).
The physiological relevance of the morphological
changes in these neurons would impact on the functional in-
tegrity of these neurons including disturbances in connectiv-
ity and how information is processed (Weinberger, 1999). As
a result, compromised ﬁne-tuning of interneuron function
in the epileptic hippocampus may lead to the reduced
Antiepileptic/neuroprotective effects of CBD in hippocampus
British Journal of Pharmacology (2018) 175 2097–2115 2111
inhibition of pyramidal cells (Lancaster and Wheal, 1984;
Cornish and Wheal, 1989; Kobayashi and Buckmaster,
2003). Together, the potentiation of excitatory mechanisms
and the ineffective control of persistent excitation would
synergistically facilitate the generation and propagation of
epileptiform activity (de Lanerolle et al., 1989).
The mechanisms of how CBD exerts a neuroprotective ac-
tion could be related to reduced oxidative stress. In the present
study, administration of KA to rats to induce epilepsy caused
persistent activation of glutamate AMPA/kainate receptors trig-
gering a sustained neuronal inﬂux of Na+ and Ca2+, causing
prolonged depolarization and prolonged Ca2+ inﬂux into the
cytoplasm. However, previous studies suggest that CBD exerts
an activity-dependent biphasic control over Ca2+ levels (Ryan
et al., 2009); hence, it is likely that in our experiments, CBD
treatment of epileptic rats exerted a neuroprotective function
by preventing intracellular Ca2+ overloading during hyperactiv-
ity, thus halting oxidative stress. This would trigger mitochon-
drial oxidation (Hajnoczky et al., 2006), contributing to the
degenerative process of neurons (Liang et al., 2000; Patel,
2004; Waldbaum et al., 2010).
We observed an increase in PV- and CCK-expressing cell
densities, as well as an increase in the dendritic length after
CBD treatment, and while the notion of adult neurogenesis
has been controversial, it is evidenced by studies that show
modulation of various receptors and their signal transduction
pathways, such as GPCRs (Kaplan and Hinds, 1977; Doze and
Perez, 2012; Goncalves et al., 2016). For example, neurogenesis
in both embryonic and cultured adult hippocampal neural
stem and progenitor cells has been shown via the activation
of GPCRs, CB1 receptors and ERK signalling by CBD and other
synthetic cannabinoids (Jiang et al., 2005). Furthermore, CBD
has been implicated in CB1 receptor-mediated proliferation
and maturation of progenitor cells (Wolf et al., 2010). While
the established CBD actions via CB1 receptors are few, it could
be postulated that the proneurogenic effects of CBD in the re-
ported results are a consequence of sequential activation
GPCRs and CB1 receptors. Therefore, CBD could be potentiat-
ing a morphological self-repair mechanism of the surviving
PV- and CCK-expressing neurons via neurogenesis in the adult
epileptic hippocampus of rats.
In conclusion, the impaired morphology of interneurons
and pyramidal cells reported here and by others following sei-
zure activity probably contributes to impaired inhibitory
mechanisms in epileptic hippocampi, and existing evidence
of reorganization of the neuronal circuitry probably contrib-
utes to the generation and propagation of hyper-synchronous
activity of large neuronal populations that underlie epilepti-
form activity. A decrease in ﬁring properties of pyramidal cells
in the hippocampus caused by CBD suggests that it reduces
excitability, while an increase in ﬁring properties at speciﬁc
interneurons suggests that CBD will enhance inhibition at
some synapses, ultimately leading to a rebalance of excita-
tion, thus supporting our hypothesis. The precise cellular
mechanism of the pre- and postsynaptic receptors involved
in these changes, however, requires further investigation.
Pharmacoresistance to conventional anti-epileptic agents is
an unresolved problem in the ﬁeld of epilepsy resulting in a
higher fraction of failed treatment in epileptic patients. The
mechanisms of action by which currently available pharma-
cological anti-epileptic drugs work, for example, blocking
voltage-gated sodium channels, only suppress neuronal dis-
charge by a rate-dependent mechanism. Na channel blockers,
such as carbamazepine and valproate, are widely used in the
treatment of TLE, but the dangerous side effects and the asso-
ciated increased risk of suicide often limit the use of the drug
or result in the use of a second anti-epileptic treatment (adju-
vant therapy). CBD is amulti-targeted naturally-derived plant
compoundwith little to no side effect proﬁle. Thismakes CBD
a desirable candidate for the treatment of TLE that could play
a vital antiepileptic and neuroprotective role in the epileptic
CNS by enhancing selective inhibition and dampening exci-
tation, which would ultimately reduce seizure activity and
prevent neuronal death.
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